Is Calocurb clinically proven? The C4 trial in numbers

Is Calocurb clinically proven? Yes, to this extent: one 24-week randomised, double-blind, placebo-controlled trial of the finished capsule, peer-reviewed and open access, funded by Calocurb Ltd, found the treatment arm lost 4.3% of body weight against 0.5% on placebo, a placebo-subtracted gap of 3.8 points, at 500 mg daily, which is the label’s maximum dose rather than its standard one.

That is the whole answer. The rest of this review is how we got to it, because the brand’s home page compresses the same trial into “9x more weight loss than willpower alone” and a reader deserves to see the numbers before the multiple.

This is a reading, not a test. Nobody at this desk has taken the product. On 11 September 2026 we read the open-access paper in Obesity Pillars, the NutraIngredients report of 3 August 2026 that carries the per-arm figures and the funding line, and the Calocurb home page for the label dose and the claims.

Is Calocurb clinically proven, and by which trial?

The paper appeared in Obesity Pillars on 17 July 2026, published by Elsevier on behalf of the Obesity Medicine Association, received 3 May and accepted 8 July, under a CC BY-NC-ND licence. The corresponding author is Edward Walker of the Bioeconomy Science Institute in Auckland. The trial is registered with the Australia and New Zealand Clinical Trial Registry as ACTRN12625001011471.

The design, from the abstract: 150 adults were randomised and put through a 24-week weight-loss programme of monthly lifestyle-advice group seminars. Each day they took either placebo or 500 mg of bitter hop extract, half the dose at least an hour before each of the two main meals. Weight, bioelectrical impedance (BIA) body composition, and appetite and craving ratings were taken every four weeks. NutraIngredients adds that participants were in New Zealand, aged 18 to 45, with a BMI of 25 to 35.

One hundred and twenty-eight finished. The abstract reports the hop group lost 3.8% more body weight and 3.9 kg more fat mass than placebo, both at p below 0.05, and 4.3% of body weight and 4.5 kg of fat mass against its own baseline. Visceral fat area fell proportionally, and neither group lost BIA-estimated skeletal muscle.

How big is the effect once you take the multiple off?

The brand’s headline is a ratio. Ratios against a placebo arm that barely moved get large quickly, so here are the per-arm figures as NutraIngredients reports them, and the arithmetic done both ways.

Two things in that table need saying in words.

First, the ratio. Divide 3.8 kg by 0.4 kg and you get 9.5; divide the percentages and you get 8.6. Both round to the brand’s “9x”. The same trick on fat mass gives 4.5 divided by 0.7, about 6.4 on the rounded figures, and the brand prints 6.5x. None of this is false. It is just that “nine times” describes a 0.4 kg placebo result as much as it describes the product. The number that tells you what changed is 3.8 points, or about 3.4 kg, over six months of also attending monthly diet seminars.

Second, the dose. The trial gave 500 mg of extract a day. The brand’s home page, as we read it, describes its capsules as 125 mg, recommends building up to a standard dose of two a day, and sets four a day as the maximum. Four times 125 mg is 500 mg. So the published result belongs to the label’s ceiling, and a buyer following the standard two-capsule routine is taking half the studied amount. Whether that routine produces half the effect, or any of it, is not something this trial can tell you, because it did not test it.

We wrote about this pattern in general in our piece on what “clinically studied” is asked to carry. Calocurb is a better case than most, because the study is real and the finished product was tested. The gap here is between the dose studied and the dose sold as standard.

What about the “four human clinical studies”?

The home page says four human clinical studies published in US medical journals, 15 years of research and over $30 million invested. We have verified one journal paper, the one above. NutraIngredients’ account, and Walker’s quotes in it, are that the earlier studies showed reduced hunger and calorie intake and that C4 is the first to show those effects translating into body composition over the longer term. We have not read the earlier papers, so we make no finding about their design or results, and the brand’s “30% less hunger, 40% fewer cravings, 18% fewer calories after an hour” figures stay the brand’s.

The distinction matters for the query. “Clinically proven” to reduce weight rests on one trial. “Clinically studied” for appetite rests on more, none of which we have read.

Who dropped out, and why?

This is the part of the paper the brand pages we read do not carry, and it is the part a buyer should read first.

Twenty-two of 150 did not complete: 12 on placebo, 10 on the extract. Two people, one in each arm, withdrew citing side effects of the capsule; the one on the extract reported diarrhoea, the one on placebo reported malaise. Beyond those, six participants in the hop arm took less than the prescribed dose for most of the study because they could not tolerate it, five at half dose and one at a quarter. Their symptoms were diarrhoea only in three, diarrhoea and nausea in two, and nausea only in one.

Six of the roughly 75 randomised to the extract is about 8%; NutraIngredients rounds it to “around 10%” and attributes it to the dose-escalation phase. Either way, roughly one in ten people on the studied dose could not stay on it. The paper says there were no significant changes in blood safety markers in the hop group, which we read in the results text rather than in a table.

One more line from the methods. The power calculation said 50 per group would do; the authors recruited 75 per group partly, in their words, because of “regulatory requirements to meet health claim standards in the Australian region”. That is the company telling you the trial was built to support a claim.

Is Calocurb FDA approved, or approved anywhere?

Not as a drug, and not by any regulator in the material we read. Calocurb is sold as a dietary supplement. The brand’s own footer, read on 11 September 2026, states that statements about its products have not been evaluated by the United States FDA, New Zealand’s Ministry of Health (Medsafe) or the European Medicines Agency. The brand describes its ingredients, Amarasate, rosemary leaf extract and vegetable oil, as GRAS; that is the brand’s description, and we did not locate an FDA notice for it in this review.

For scale, the FDA maintains a draft guidance on developing drugs and biological products for weight reduction, issued January 2025, replacing a 2007 draft, and still out for comment. It applies to drugs and biologics. A supplement trial is not held to it, and we do not pretend it is; we mention it because a reader comparing a 3.8-point result with a prescription GLP-1 drug is comparing across two different rulebooks. Walker himself told NutraIngredients that Calocurb is not intended to compete with those medicines. The product is nonetheless named “GLP-1 Activator” on its product page, a naming habit we traced across the category in how GLP-1 drugs reshaped supplement marketing language.

Pros and cons

Verdict

If you buy it, buy on the paper’s terms: the studied regimen is 250 mg an hour before each of two main meals, which on 125 mg capsules is two capsules twice a day, alongside a diet programme, for six months, in adults under 46. Expect a few kilograms more than you would lose otherwise, not a transformation, and expect the first week to be the hard part.

Frequently asked questions

Is Calocurb a scam, or does it actually work?

It is not a scam in the sense this site usually meets: the product has a registered, peer-reviewed, placebo-controlled trial of the finished capsule, and the trial reported a real difference. The size of that difference is 3.8 percentage points of body weight over 24 weeks at the label’s maximum dose, in adults aged 18 to 45, in a trial the company paid for. Whether that is worth the price is your sum, not ours.

What are the side effects of Calocurb?

Gastrointestinal, on the paper’s account. Of the 22 people who left the trial early, one on the hop extract withdrew citing diarrhoea. Six others on the extract cut their dose for most of the study because of tolerability: three reported diarrhoea only, two diarrhoea and nausea, one nausea only. The brand’s own page says loose stools can occur in the first 24 to 72 hours. The brand says it is not tested for use under 18 or in pregnancy.

How long does Calocurb take to work?

The only weight outcome we have read is at 24 weeks, with measurements every four weeks along the way; the paper’s abstract does not give an earlier timepoint at which the two arms separated. The brand’s own site says the product is most effective when taken for at least three months. The appetite figures it quotes, such as 30% less hunger after an hour, come from earlier studies we have not read and cannot vouch for here.

Is Calocurb FDA approved?

No. Calocurb is sold as a dietary supplement, and the brand’s own footer states that statements about its products have not been evaluated by the United States FDA, New Zealand’s Medsafe or the European Medicines Agency. The FDA’s January 2025 draft guidance on developing weight-reduction products covers drugs and biologics, is still a draft, and a supplement trial is not held to it.

Does Calocurb increase GLP-1?

The brand says its hop extract activates GLP-1, CCK and PYY, and the paper’s own keywords list GLP-1 and bitter taste receptors. The C4 trial as we read it reported weight, fat mass, visceral fat, muscle estimates and appetite ratings; it did not report a GLP-1 blood level in the abstract or the sections we read. So the hormone claim rests on earlier mechanistic work, not on this trial.

Calocurb is sold as a dietary supplement, and by the brand’s own account neither the FDA, Medsafe nor the EMA has evaluated what it says about the product. Nothing here diagnoses, treats, cures or prevents anything, and none of it is medical advice. The trial excluded people under 18 and the brand says the product is untested in pregnancy or breastfeeding; if you take medication or have a digestive condition, the diarrhoea and nausea figures above are a reason to ask a pharmacist before the first capsule. We reviewed a fibre product against its own trial in our FORMI review; the method there is the method here, and the weight-loss aisle would be a better place if every brand made it this easy to run.